The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

This big pharma stock still faces significant challenges in the new year.

Pfizer is one of the world's largest pharmaceutical companies. Even after losing more than half of its value, it still has a ...

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

Pfizer is investing in oncology and GLP-1 drugs, among other things, to keep its growth prospects bright. Western Union is ...

It's a great opportunity to "buy low." ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.